Introduction
Myotonic dystrophy type 1 (DM1) is a progressive multisystemic disease caused by a trinucleotide (CTG) expansion in the 3 0 -untranslated region of the dystrophia myotonica protein kinase gene on chromosome 19. 1 The range of CTG repeat numbers in myotonic dystrophy type 1 is 50-4000, in which repeat sizes of 50-80 may be associated with mild clinical phenotypes and large repeat expansions up to 4000 are often found in severe, mostly congenital forms of the disorder. It is characterized by common cognitive deficits and potential brain involvement in addition to the cardinal muscular and systemic symptoms. Daytime sleepiness, fatigue, executive and visuospatial dysfunctions and anxious personality traits (deteriorating with age) are among the common manifestations in patients with the classic adult (aDM1, age at onset !20 years) or juvenile (jDM1, age at onset <20 years) forms of DM1. 2 The pathogenesis of central nervous system (CNS) symptoms is not entirely clear. Neurofibrillary degeneration with intraneuronal accumulation of abnormally modified microtubuli-associated tau protein has been demonstrated in DM1 brains connecting this disorder to a subset of neurodegenerative diseases. [3] [4] [5] Brain involvement in DM1 has been demonstrated in vivo using different neuroimaging techniques. In these patients, routine brain magnetic resonance imaging (MRI) often shows nonspecific pathological findings such as white-matter hyperintensities (WMHs), ventricular enlargement and brain atrophy. [6] [7] [8] The effect on WM was quantified either by morphometric techniques (brain volumetry or voxel-based morphometry (VBM)) or assessed nerve fiber integrity using diffusion-tensor imaging (DTI) and tractography. 9, 10 The correlations of brain morphological changes with clinical and cognitive features in DM1 have been assessed by several reports with conflicting results. Disconnection of cortical regions by changes of the interconnecting WM is a potential mechanism for cognitive dysfunction in various neurological disorders and may also be responsible for CNS symptoms in myotonic dystrophies. [11] [12] [13] The goal of this study was to investigate WM abnormalities and their effects on clinical and cognitive deficits in a small, phenotypically and genotypically well-characterized cohort of DM1 patients.
Materials and methods
A total of 13 DM1 patients attending our Neuromuscular Outpatient Clinics were enrolled in the study and their data were evaluated retrospectively. The diagnosis of DM1 was based on clinical examination, electromyography (EMG) findings and Southern blot analysis showing the CTG repeat expansion on chromosome 19. Patients with history of congenital DM, traumatic brain injury history, intracranial mass, other major medical, neurological or psychiatric illnesses, and/or any contraindication to MRI were excluded from the study. MRI scans from three patients were excluded because of movement artifacts and lack of medical records. Therefore, 10 DM1 patients were included in the analysis. Neurological evaluation consisted of history collection and assessment of muscle involvement using the Muscular Impairment Rating Scale (MIRS). 14 Genetic assessment performed during outpatient clinic follow-up consisted of molecular analysis of CTG triplet repeat expansions including small-pool polymerase chain reaction (PCR) analysis using serial dilutions of EcoR1 digested genomic DNA (50-500 pg). EMG examination of all patients demonstrated myotonic discharges and myopathic changes. MRI scans were acquired using a 3 T system. All MRI postprocessing was performed by observers blinded to subject's identity. A comprehensive analysis of WMHLs using a visual scale (Wahlund and age-related whitematter changes (ARWMC) scale) 15 and brain atrophy was performed. WM lesion (!5 mm) quantifications on T2-images consisted of grading within five regions, separately for each hemisphere, ranging from 0 (no lesions) to 3 (diffuse involvement of the entire region). Cerebral atrophy was evaluated relative to age. Brain atrophy was rated as follows: no, mild, moderate and severe.
Cognitive 
Results
The age range of 10 (seven male/three female) patients was 19-57 years (37.30 AE 14.47). Patients' clinical data are shown in Table 2 . EMG showed myotonic and myopathic motor unit potentials (MUPs) in all patients. Mild cognitive impairment was detected in 72% of the patients. Minimal impairment in the learning and recall phases of verbal memory was also detected. Nonverbal memory impairment was mild especially in recording and recall phases. Visualspatial/visual-constructive abilities were mildly impaired in three of the patients. With respect to evaluation of language functions, mild dysarthric speech was detected in three patients and impairment in writing skills in one 
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The Neuroradiology Journal 30 (1) patient. The Frontal Assessment Battery showed impairment in the ability to maintain attention and working memory, difficulty suppressing inappropriate responses, and reduction in categorical and lexical fluency (lexical fluency damage was more pronounced than categorical fluency). MoCA scores ranged between 24 and 30 and the average was 28.10 AE 1.85. Table 3 shows the detailed score of the neuropsychological tests. WMHLs were observed in 40% (n: 4) of the patients (Figure 1 ). Wahlund score of all patients with WMHLs and the subscore according to the anatomical distribution is shown in Table 4 . Wahlund score ranged between 0 to 3 and the average score was 0.70 AE 1.05. A total of five patients did not show brain atrophy (50%). Mild brain atrophy was detected in three (n: 4; 40%) and moderate brain atrophy in one (n: 1; 10%) patient, respectively. When evaluating the relationship between the presence of WMHLs to age, gender and MoCA scores, a statistically significant difference was not found (p ¼ 0.285; p ¼ 0.324; p ¼ 1.000) ( Table 5 ). Mild cognitive impairment was prominent particularly in patients with temporal involvement. A negative correlation (19.4%) that was not statistically significant (r ¼ -0.194; p ¼ 0.592) was found between Wahlund and MoCA score. Also, a positive correlation that was not statistically significant (r ¼ 0.216; p ¼ 0.549) was detected between Wahlund score and brain atrophy ( Table 6 ).
Discussion
The progressive decline in working capacity and physical activity in patients with DM1 has in general been attributed to the progression of muscular symptoms and respiratory insufficiency. So far there has been an attempt to demonstrate the clinical relevance of the abnormal neuropsychological test scores and neuroimaging findings in patients with DM1. We present clinical, cognitive and cranial MRI data in a relatively small series of patients with noncongenital DM1. Our DM1 patients showed generally a moderate muscular impairment, impaired cognitive performance over a broad range of functions, including frontal, visuospatial, naming and memory abilities and WM abnormalities. The degree of cognitive impairment in classical aDM1 patients is greatly variable, and significant cognitive impairment is observed only in some patients. Symptoms such as mild depression and anxiety as well as deficits of visuospatial abilities, executive functions, reasoning and naming have been frequently reported in DM1 patients. 16, 17 We demonstrated WMHLs in DM1 patients mainly located in the anterior temporal, frontal, parieto-occipital and periventricular WM regions (Figure 1 ). Several MRI studies have shown that DM1 patients have WMHLs, which are generally more prominent in the frontal, parietal and temporal regions and increase with the progression of the disease. 2, [5] [6] [7] 18, 19 Qualitative scales were mostly used to evaluate the spatial distribution of WMHLs. In this study we provide a quantitative assessment of the anatomic location of WMHs using the Wahlund scale. These radiological changes may be explained by myelin alterations, changes in interaxonal water content and decreased magnetization transfer ratio of the normalappearing WM observed in DM1 patients. 20 Although based on a small number of patients, our data confirm selective progressive frontal lobe function (attentional) involvement. Several previous studies suggested a relationship between the extent of WMHLs and cognitive deficits in DM1 patients although other studies did not confirm these findings. [3] [4] [5] [6] [7] 21 In our DM1 patients, the severity of cognitive deficits was more prominent in patients with WM damage and in particular, WMHL burden was associated with memory, executive, reasoning, and visuospatial impairments. In aDM1 patients MRI findings have been mostly related to disease duration, CTG repeat expansion size, MIRS score, manual motor performance and facial muscle volumes but rarely with cognitive impairment. 8, 22 A correlation between WM damage and intelligence tests was reported in congenital and jDM1. 23 These conflicting results concerning the correlation of structural brain abnormalities, clinical features and cognitive/behavioral findings can be attributed mainly to the high variability of the DM1 clinical presentation based on the somatic mosaicism of CTG repeats, but also to the small and heterogeneous cohorts of patients involved in previous reports including ours. The nature of CNS abnormalities revealed by MRI is still unclear:
The ones located at the temporal poles seem to be characteristics of the disease, while others, small, diffuse WMHLs suggest findings similar to the age-related alterations.
The retrospective design of our study does not allow concluding on the neurodegenerative and/or developmental origin of the brain abnormalities observed in DM1. Still, the exploratory nature of the performed neuropsychological tests and WM lesions analyses provide data that support the hypothesis of a 
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The Neuroradiology Journal 30 (1) degenerative process present in DM1 patients. The lack of a control group and the relatively small number of the included patients constitute limitations in this study.
Conclusion
Overall, these results suggest that DM1 is characterized by brain involvement, and WMHLs may be responsible for the global intellectual dysfunctions in aDM1 patients. Studies including larger number of patients may shed light on the different mechanisms underlying the brain involvement and their relationship to the cognitive impairment in aDM1. 
